An estimated 20% of all patients with cancer will develop brain metastases, with the majority
of brain metastases occurring in those with lung, breast and colorectal cancers, melanoma …

Patients with advanced cancer generate 4 million visits annually to emergency departments
(EDs) and other dedicated, high‐acuity oncology urgent care centers. Because of both the …

Background: Anaplastic thyroid cancer (ATC) is a rare but highly lethal form of thyroid
cancer. Since the guidelines for the management of ATC by the American Thyroid …

Purpose Treatment with programmed cell death-1 or programmed death ligand 1 (PD-(L) 1)
inhibitors is now standard therapy for patients with lung cancer. The immunosuppressive …

Immune checkpoint inhibitors (ICIs) can elicit toxicities by inhibiting negative regulators of
adaptive immunity. Sometimes, management of toxicities may require systemic …

PURPOSE Baseline use of corticosteroids is associated with poor outcomes in patients with
non–small-cell lung cancer (NSCLC) treated with programmed cell death-1 axis inhibition …

Brain metastases (BMs) occur in 10% to 20% of adult patients with cancer, and with
increased surveillance and improved systemic control, the incidence is likely to grow …

Background: Anaplastic thyroid cancer (ATC) is a rare but highly lethal form of thyroid
cancer. Rapid evaluation and establishment of treatment goals are imperative for optimum …

Purpose To systematically review the evidence for the radiotherapeutic and surgical
management of patients newly diagnosed with intraparenchymal brain metastases. Methods …

Breast cancer is one of the most prevalent malignancies in women worldwide. Early-stage
breast cancer is considered a curable disease; however, once distant metastasis occurs, the …